Previously we undertook studies to assess the inductive response of prototypical inducers in hepatocyte monocultures and the long term co-culture model, HepatoPac™, using cryopreserved hepatocytes from the same donors (Dixit et al., 2015) . We noted that the rifampicin EC 50 generated using the HepatoPac model corresponded better to the EC 50 based upon clinical data compared to data generated in the monoculture system. We postulated that there may be differences in the functioning of uptake transporters between the two systems which may have led to the EC 50 difference. In this study, we characterized the functional activity of multiple uptake transporters in the two systems using cryopreserved hepatocytes from the same donors. Our data suggests that uptake transporter activity is higher in HepatoPac compared to the monoculture system. As a follow-up to this study, we measured the intracellular concentrations of rifampicin and bosentan which are known substrates of uptake transporters and observed significantly higher intracellular concentrations of both compounds in HepatoPac relative to the monoculture system. This finding equated to lower CYP3A4 EC 50 values in the HepatoPac system compared to the monoculture system for both mRNA and activity. In parallel, no significant EC 50 shift was observed for carbamazepine and phenytoin which are not known to be substrates of uptake transporters. Our data suggests that next generation liver models, like HepatoPac, may be a useful in vitro tool to quantitatively predict DDIs when it is known that the perpetrator is also a substrate of drug transporters.
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INTRODUCTION
In vitro approaches are now regarded as a critical first step in the assessment of the drug-drug interaction (DDI) risk of compounds (FDA, 2012) . However, despite improvements in predicting DDIs based on in vitro evaluations, unexpected DDIs do occur that could be due to unknown variables, such as the involvement of drug transporters, which are not accurately measured with currently available in vitro tools.
As early as 2004, Lam and Benet highlighted the interplay between drug transporters
and metabolism, as well as the limitations of using microsomes for clearance predictions when compounds are substrates of drug transporters (Lam and Benet, 2004) . Thereafter, Frassetto et al. (2007) showed that CYP3A4 activity, as measured by the erythromycin breath test, was decreased with rifampicin, which is an organic anion transporter (OATP)1B1 inhibitor, and increased with lansoprazole, which is an inhibitor of P-glycoprotein (P-gP).
Since the publication of these seminal papers, there have been several articles highlighting the importance of factoring in the interplay between drug transporters and metabolism and subsequent mechanistic models to understand the DDI-risk of compounds (Pang et al., 2009; Li et al., 2014) . However, there is a lack of understanding regarding the interplay between drug transporters and CYP3A4 induction. Cultured human hepatocytes, in either the 2D or sandwich cultured models, are the mainstay for the assessment of induction-based DDI risk using static models such as the relative induction score (RIS) model (Fahmi et al., 2010; Einolf et al., 2014) . observed DDIs. Two of the compounds (rifampicin and bosentan) are known to be substrates of uptake (OATP1B1/3) transporters (Paul et al., 2005; Treiber et al., 2007) .
While limited, there have been publications describing changes in uptake transporter activity with culture time and that optimal expression and functionality levels may not be attained during the monocultures short culture period (3-5 days) (Ulvestad et al., 2011; Zhu et al., 2014) . This was recognized previously by Shou et al. (2008) who attempted to develop a more quantitative model to predict induction-based CYP3A4 DDIs in the clinic. They concluded that the DDI risk for bosentan when co-dosed with CYP3A4
substrates such as ethinyl-estradiol, glyburide, and sildenafil, using induction data generated with the standard monoculture model is under predicted because bosentan is a substrate of OATP.
There is now a heightened interest in using technologies that maintain their differentiated in vivo-like phenotype as the need for more predictive in vitro next generation hepatocyte models increases. One such technology is the HepatoPac model in which hepatocytes are co-cultured with 3T3 fibroblasts in a precise microscale architecture for at least 9 days prior to use in an experiment. This extensive recovery period allows the hepatocytes to regain their polarity and form a biliary network that is essential for proper functioning of canalicular and sinusoidal transporters (Khetani and Bhatia, 2008) . In contrast, hepatocytes cultured in a conventional monolayer have limited cell-cell and cell-matrix interactions with reduced polarization, bile canaliculi formation, and metabolic activity (Berthiaume et al., 1996) . Monocultured hepatocytes remain viable in culture for 3-5 days while HepatoPac cultures display long-term viability and metabolic function over several weeks. In our earlier publication, we conducted an evaluation of the Hepatopac model as a tool to assess induction-based DDI risk in the clinic (Dixit et al., 2015) . During this assessment, we speculated that the potency of rifampicin could be influenced by differences in the activity and expression of transporters in the two culture models given that the EC 50 generated with the HepatoPac model (0.1 µM) correlated better with the modeled clinical EC 50 of rifampicin which was predicted to be as low as 0.05 µM using Simcyp™ (Kharasch et al., 2011; Dixit et al., 2015) . In contrast, the EC 50 of rifampicin in monocultured or sandwich cultured cryopreserved hepatocytes is in the range of 0.5-1 µM (Zhang et al., 2014; Dixit et al., 2015) .
In order to expand our understanding of the interplay between drug transporters and CYP3A4 induction, the objectives of this study were to: 1. Compare activity differences for uptake transporters, in the same batch of cryopreserved hepatocytes, when cultured in the monoculture and HepatoPac systems; 2. Assess the impact of differences in transporter activity on intracellular concentrations of perpetrator compounds between the two systems; 3. Determine if differences in intracellular concentrations of perpetrator compounds translates to changes in EC 50 for compounds which are substrates and non-substrates for uptake transporters.
This article has not been copyedited and formatted. The final version may differ from this version. HepatoPac: HepatoPac and 3T3-J2 murine embryonic fibroblast only cultures were acquired from Ascendance Biotechnology and were prepared as previously described (Khetani and Bhatia, 2008) . Cryopreserved hepatocytes were seeded at a density of 30,000 and 5,000 viable cells/well with fibroblasts in 24 well and 96 well plates respectively. 3T3 fibroblast only cultures were seeded at a density of 90,000 cells/well in 24 well plates. Both HepatoPac and 3T3 fibroblast only cultures were maintained in proprietary media at Ascendance Biotechnology for 7-9 days post-seeding prior to initiating experiments. The cells were cultured in an incubator with 10% CO 2 and 95% relative humidity at 37°C. .cm 2 were used for permeability measurements.
Cryopreserved monocultured human hepatocytes:
Uptake Assay:
HepatoPac cultures were used 9-12 days post-seeding while monocultures were used 24 hours post-seeding for uptake experiments. Dosing solutions were prepared using radiolabeled compound supplemented with unlabeled compound to achieve the desired dosing concentration. For uptake transporter assessment, probe substrates were applied at the following concentrations: 0.5µM [ Total DPM = Total radioactivity in reaction medium.
Total pmol = Total concentration of substrate in reaction medium. 
Permeability Assessment with MDCK cultures:
The assay procedure was conducted using a Tecan Genesis automated liquid with shaking for 60 min. Aliquots (50 μL) were removed from the receiver and donor compartments at 0 and 60 minutes, then transferred into 96-well microtiter plates for LC-MS/MS analysis as described below. At the end of the permeability experiment, 100 μ M lucifer yellow was added to the apical side of the monolayers to confirm the integrity of the cell monolayer during incubation with the test compounds. Metoprolol, a high permeability marker, was used as a control.
The apparent permeability coefficient (P app ) of the test article and controls is determined using the following equation:
Rate of appearance of the compound in the receiver compartment, which is measured as the change in total quantity in the receiver compartment over time (slope of linear regression).
Area: Surface area of the membrane (0.143 cm 2 ).
C 0 : Initial concentration of a compound in donor compartment.
CYP3A4 Induction Assay:
HepatoPac cultures were treated with test compounds 9-12 days after plating. with 5% CO 2 and 95% humidity at 37°C.
In both culture systems, control wells were treated with 0.1% DMSO, fresh dosing solution was applied every 24 hours for 2-3 days, and all experiments were done in triplicate.
CYP3A4 Activity Assay:
Following compound treatment, supernatants were removed and the cultures were washed with either application medium (HepatoPac) or HBSS (monoculture).
Cultures were then incubated with 15µM Midazolam in either application medium Standard curves were made in matrix and used for concentration calculations.
Data were analyzed using Analyst® version 1.6.2 (SCIEX, Framingham, MA).
Relative Expression of mRNA:
Following compound treatment and CYP3A4 activity incubations, the cultures were washed with HBSS and stored in RNAlater at -20°C until the RNA isolation protocol was performed. The MagMax-96 Total RNA Isolation Kit was used following to the manufacturers' protocol to isolate total RNA from each culture well. Concentration and quality of the isolated RNA was measured in representative samples using a Nanodrop2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). 50ng of total RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit, according to the manufacturers' protocol. Quantitative PCR reactions were carried out using the TaqMan® Fast Advanced Master Mix, human GAPDH probe, and cDNA primer for CYP3A4. All data were normalized to the expression of the housekeeping gene, GAPDH, and fold change in mRNA expression of CYP3A4 over the solvent control was calculated using the
This article has not been copyedited and formatted. The final version may differ from this version. 
Induction Data Analysis and Fitting:
Data from the concentration-response curves were fit to a three-parameter sigmoid (Hill) model, using equation 3, to calculate the EC 50 and E max values.
The baseline value of induction (E0) was fixed to 1. Data was fitted with Graphpad Prism 5.0, La Jolla, CA.
Statistical Analysis:
The data are shown as the mean value with bars indicating the standard error (SE) for n≥3. Data analysis was done using GraphPad 5.0 using two-way analysis of 
RESULTS:
Basal expression of drug transporter genes in HepatoPac and monoculture systems As described in Dixit et al. (2015) , the basal gene expression of 76 drug disposition genes were evaluated in both HepatoPac and monoculture systems using the same cryopreserved hepatocytes from three donors in both culture models (Supplemental Table 1 1994; Breidert et al., 1998; Hirano et al., 2006; Ishiguro et al., 2006; Konig et al., 2006) . with a 4°C passive uptake control and the raw data was normalized to this background value (data not shown). As indicated in Figure 1 and Table 1 , the uptake of pitavastatin (OATP1B1), telmisartan (OATP1B3), TEA (OCT1), and TCA (NTCP) was significantly higher in the HepatoPac system compared to monoculture system in all three donors (**P<0.01). However, estrone-3 sulfate (OATP1A2) uptake was similar in both
HepatoPac and monoculture in donors Hu1624 and BPB and modestly higher (1.9 fold) in donor NON (Table 1 ). Higher gene expression in HepatoPac correlated to higher activity for uptake transporters OATP1B3 and OCT1. OATP1B1and NTCP also showed higher activity in HepatoPac compared to the monoculture system even though the basal gene expression for this transporter was similar in the two culture models.
Intracellular Concentrations of Rifampicin and Bosentan in HepatoPac and
Monoculture Systems
Given the differences in transporter activity between the HepatoPac and monoculture systems, we evaluated the intracellular concentrations of actively transported compounds rifampicin and bosentan using the cryopreserved hepatocytes from donor NON. We selected donor NON as it represented the highest OATP1B1 and OATP1B3 uptake activity of the three donors. We measured total intracellular uptake of
passive diffusion (Larregieu and Benet, 2014) . In both models, total uptake of rifampicin and bosentan increased with time up to 4 hours. Rifampicin at 0.01 µM and bosentan at 0.01and 1 µM showed significant reduction in the total uptake after 4 hours which could be due to depletion of compound in the media. The total uptake of both rifampicin and bosentan was significantly greater (**P<0.01) in HepatoPac compared to monoculture at all three concentrations tested (Figure 2 ). On the contrary, the uptake of [ Given that HepatoPac is a co-culture model with a 3:1 ratio of 3T3 fibroblast cells to hepatocytes, we measured the intracellular levels of all three compounds in 3T3 fibroblast cells alone, maintaining the same cell density as used in the HepatoPac system. Given the low permeability of rifampicin and bosentan (Supplemental Table 2) the measured intracellular levels of rifampicin and bosentan was minimal in the fibroblast cells compared to HepatoPac co-culture at all three concentrations (0.01, 1 and 10 µM) (Figure 2A and B) . However, metoprolol intracellular levels in fibroblast cells was found to be significant and similar to HepatoPac uptake ( Figure 2C ) indicating substantial contribution by fibroblasts in the uptake of metoprolol in the HepatoPac coculture due to its' high passive permeability. Similar to metoprolol, CYP3A4 inducers, phenytoin and carbamazepine, are also highly permeable compounds and were used as passive diffusion controls in the later described induction studies (Supplemental Table 2 ). We measured the medium concentration of phenytoin and carbamazepine in cryopreserved hepatocyte cultures over a 24h incubation period and observed that both compounds achieved equilibrium with no significant parent loss (data not shown).
Impact of higher intracellular concentrations of rifampicin and bosentan on CYP3A4 induction in the HepatoPac and monoculture systems
We previously observed a 2-20 fold decrease in the EC 50 for rifampicin mediated induction of CYP3A4 mRNA and activity in HepatoPac compared to the monoculture system in three cryopreserved hepatocyte donors. However, phenytoin, a CYP3A4
inducer that is not actively taken up by hepatocytes (Patsalos et al., 2002) , only showed a 0.4-3.4 fold decrease in the EC 50 value in HepatoPac relative to the monoculture system for CYP3A4 mRNA and activity (Dixit et al., 2015) .
In the current study we followed up on our initial observations by evaluating two additional CYP3A4 inducers, bosentan and carbamazepine (Bertilsson et al., 1997; Paul et al., 2005) . Bosentan is an OATP1B1 and OATP1B3 substrate while carbamazepine served as a passive uptake control (Paul et al., 2005; Treiber et al., 2007) . Dose response curves were generated in both the HepatoPac and monoculture systems in the same cryopreserved hepatocyte donors as used in our previous study (Supplemental Table 1 ) (Dixit et al., 2015) . Fold change in CYP3A4 gene expression and activity were determined and fit to the sigmoidal E max model. The EC 50 for bosentan mediated induction of CYP3A4 mRNA in HepatoPac was 0.2 µM in all three donors in comparison to the EC 50 of 0.8-0.9 µM in monoculture demonstrating a 4-to-4.5-fold decrease in the EC 50 value in HepatoPac compared to the monoculture system. The EC 50 for carbamazepine mediated induction of CYP3A4 mRNA in HepatoPac was 14.6-16.2 µM while in monoculture it was 20.0-27.2 µM. This is a 1.2-1.9 fold decrease in the EC 50 value in HepatoPac compared to the monoculture system. The E max values were similar across both culture models for all of the compounds tested. Induction of CYP3A4 activity yielded similar results as the mRNA data for these compounds (Figure 3 and 4; Even though there are no published reports of changes in OCT1 expression and function in cultured human hepatocytes over time, Tchaparian et al. (2011) conducted studies in sandwich-cultured rat hepatocytes and noted that Oct1 exhibited a 3-and 4-fold decrease in expression and activity on day 2 and day 4, respectively, relative to that on day 0, whereas the reduction in Ntcp expression and function was greater than 5-fold.
While Ramsden et al. (2014) showed that active uptake by OATP1B1
(rosuvastatin) and NTCP (TCA) can be measured using the HepatoPac model, in the present study we make a direct comparison of the function of both transporters in the HepatoPac and monoculture models using cryopreserved hepatocytes from the same donors ( Figure 1 , Table 1 ). In addition to OATP1B1, we also observed significantly higher uptake activity for other important uptake transporters such as OATP1B3, OCT1
and NTCP in the HepatoPac compared to the monoculture model in all three cryopreserved hepatocyte donors ( Figure 1 , Table 1 ). Although the model substrates used in the functional assessment were relatively selective to the transporters tested, the possible involvement of other transporters cannot excluded owing to their overlapping substrate specificity (Hirano et al., 2004) .
Having established that there are functional differences in transporter-mediated uptake between the two systems, we sought to understand how this would impact the intracellular concentration of compounds that are both substrates of uptake transporters as well as inducers of CYP3A4. Even though it is known that intracellular drug concentrations are fundamentally important to accurately predict DDIs, they are difficult to quantify directly in humans. Typically, unbound plasma drug concentrations are used DDI-risk (Shou et al., 2008; Chu et al., 2013) . While multiple compounds are used for validation and calibration of hepatocyte lots for CYP3A4 induction predictions using static models such as RIS (Fahmi et al., 2008) , to our knowledge, only rifampicin and bosentan are known to be substrates of uptake transporters (Supplemental Table 2 ). As described earlier, Shou et al. (2008) In order to understand the implications of higher intracellular levels of rifampicin and bosentan in the HepatoPac model on CYP3A4 induction, we conducted induction studies in both HepatoPac and monocultured hepatocyte systems using cryopreserved hepatocytes from the same donors (Supplemental Table 1 ). As noted earlier, in our previous publication, the EC 50 for rifampicin generated with the HepatoPac model (0.1 µM) correlated better with the modeled clinical EC 50 of rifampicin which was predicted to be as low as 0.05 µM using Simcyp™ (Kharasch et al., 2011; Dixit et al., 2015) . In contrast, the EC 50 of rifampicin in cryopreserved monocultured or sandwich cultured hepatocytes is in the range of 0.5-1 µM (Zhang et al., 2014; Dixit et al., 2015) . Similarly, we noted a shift in EC 50 generated for bosentan in the HepatoPac system (CYP3A4 mRNA EC 50 = 0.2 µM) compared to the monocultured system (CYP3A4 mRNA EC 50 = 0.8-0.9 µM). Due to the lack of clinical dose-dependent inductive response data for bosentan we were unable to correlate the inductive response in HepatoPac to a clinical EC 50 . In addition to compounds which are actively taken up into hepatocytes we also included two compounds (phenytoin and carbamazepine) which are highly permeable and are not substrates of hepatic uptake transporters (Supplemental Table 2 ). In general, unlike for rifampicin and bosentan, the EC 50 shift for phenytoin and carbamazepine was less than three-fold for both CYP3A4 mRNA and activity, with minimal variability between the donors in the HepatoPac system compared to the monocultured system ( Figure 3C , Figure 4C , and Table 2 ). Donor BPB revealed the largest donor difference between the models. When cultured in the monoculture system we were unable to achieve a maximum induction response for bosentan and carbamazepine and thus could not confidently calculate the EC 50 . However, when BPB was cultured in the HepatoPac system, the inductive response to these compounds was similar to the other two donors used in this study. Overall, the HepatoPac induction data was more uniform and reproducible across donors compared to the monoculture system.
The interplay between different cellular functions must be considered in order to improve the predictive power of induction based DDIs using in vitro models. We have presented here evidence that HepatoPac has higher transporter activity for OATP1B1, OATP1B3, OCT1, and NTCP and that this high function correlates with higher intracellular concentration and increased induction potency of actively transported compounds. HepatoPac could be a more sensitive and valuable tool for studying compounds with complex DDIs such as those that are substrates for hepatic uptake transporters. Furthermore, studies could be performed at lower, more clinically relevant concentrations, as higher transporter functionality allows compound to enter the cell, bind to transcription factors such as PXR, and induce CYP3A4. While more research is needed to explore the full potential and limitations of this co-culture model, the work presented here demonstrated its' value as a tool for studying compounds with complex DDIs involving interplay between uptake transporters and CYP3A4 induction. a (Dixit et al., 2015) This article has not been copyedited and formatted. The final version may differ from this version. (Dixit et al., 2015) 
